REGENXBIO (RGNX) Projected to Post Quarterly Earnings on Thursday

REGENXBIO (NASDAQ:RGNX) will likely be issuing its quarterly earnings data after the market closes on Thursday, March 13th. Analysts expect the company to announce earnings of ($1.19) per share and revenue of $23.70 million for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

REGENXBIO Price Performance

NASDAQ RGNX opened at $6.25 on Thursday. REGENXBIO has a 1 year low of $5.62 and a 1 year high of $27.16. The firm has a market cap of $309.66 million, a price-to-earnings ratio of -1.24 and a beta of 1.29. The company has a fifty day moving average price of $7.51 and a 200-day moving average price of $9.32.

Wall Street Analyst Weigh In

RGNX has been the subject of several recent analyst reports. Raymond James initiated coverage on shares of REGENXBIO in a research note on Friday, February 7th. They issued an “outperform” rating and a $27.00 target price for the company. Chardan Capital reiterated a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a research note on Wednesday, November 20th. Royal Bank of Canada reiterated an “outperform” rating and issued a $30.00 target price on shares of REGENXBIO in a research note on Tuesday, January 21st. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Tuesday, February 25th. Finally, Morgan Stanley restated an “overweight” rating and set a $22.00 price target on shares of REGENXBIO in a research report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, REGENXBIO currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.70.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.